Trial Profile
BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 01 Nov 2021 Results of pooled analysis (n=3717) assessing the safety and efficacy of a bioresorbable polymer sirolimus eluting stent system (BP-SES; Orsiro) compared to a durable polymer everolimus eluting stent system (DP-EES; Xience) in the pooled population as well as in subgroups from BIOFLOW-II (NCT01356888), -IV (NCT01939249), and -V (NCT02389946) as well as the all comers registry BIOFLOW-III (NCT01553526) studies, published in the Catheterization and Cardiovascular Interventions.
- 02 Nov 2017 5-year preliminary results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 30 May 2013 Primary outcomes reported at EuroPCR, according to a Biotronik media release. Outcomes also reported in the media release.